Glasgow Asthma and Allergy Study

Cross Sectional Study to Evaluate and Associate Clinical and Laboratory Features of People With Allergic and Non-allergic Asthma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01618318

Acronym

GLAAS

Enrollment

105

Registered

2012-06-13

Start date

2012-06-30

Completion date

2013-10-31

Last updated

2013-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergy, Asthma

Keywords

Asthma, Allergy, Diagnosis, Correlation study

Brief summary

In the past, doctors separated people with asthma into two groups, those with allergic asthma (about 2/3rds of people) and those with non-allergic asthma. These labels are not much used now as the treatments for all people with asthma don't depend on this classification. However, new treatments for asthma may become available and the classification may again become important. It could be useful for clinicians to know how to identify which patients are likely to benefit from particular treatments. Additionally, some new blood tests are becoming available and some of these might help to categorise the type of asthma people have. What the study hopes to do is to identify patient features which make a diagnosis of allergic asthma more likely and to see which new blood tests are most likely to be helpful in confirming this diagnosis.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Male and female patients aged 18 years old and over with a diagnosis of asthma and having received at least two prescriptions for any asthma medication in the last 12 months, who have signed an informed consent form prior to initiation of any study-related procedure

Exclusion criteria

* under 18 years * current smokers * unwilling or unable to give informed consent * a clinical diagnosis of COPD * a history of anaphylaxis (skin prick test) * participated in any clinical study in the last 12 months

Design outcomes

Primary

Measure	Time frame	Description
Serum periostin level	1 day	This is a cross sectional study. Participants will be assessed and tests conducted at a single visit

Secondary

Measure	Time frame
Serum total IgE	1 day
Blood eosinophil count	1 day
Blood neutrophil count	1 day
skin prick test	1 day
Blood eosinophils expressing CRTh2	1 day
Spirometry	1 day
Blood CD4 cells that are positive for CRTh2	1 day

Countries

United Kingdom

Outcome results